Expanding access to advanced therapies for all cancer patients

François is a veteran executive with 30 years of experience in advanced cell and gene herapy product development across multiple therapeutic areas. His background includes leadership roles in both startups and major healthcare organizations. He previously served as President of Renovaro Biosciences, CEO of Rediens, and Global Head of Product Development at Lineage Cell Therapeutics, with prior experience at Johnson & Johnson, Medtronic, and Genzyme.

Michael is a physician-scientist with over 25 years of experience in internal medicine, developmental biology, and drug development. He has held senior leadership roles in both biotech startups and major pharma, including Centocor, Johnson & Johnson, and Incyte. He co-founded the Proof-of-Concept Team at J&J and led Global Medical Affairs at Incyte.

Ariel Rodriguez, PhD, is Head of Translational Science at Tidewave Bio, leading translational R&D for the company’s advanced therapy platform. He has extensive experience across molecular biology, preclinical development, gene-modified cellular therapies, and regulatory quality assessment, with prior roles in the U.S. and Europe spanning translational science, biologics evaluation, and advanced therapy development. Dr. Rodriguez has authored more than 25 peer-reviewed publications and is an inventor on several patent applications.

Alexander Eggermont, MD, PhD, is Head of Tidewave Bio’s Clinical Advisory Board and an internationally recognized leader in cancer immunotherapy, translational oncology, and clinical trial strategy. He is the former Director General of Gustave Roussy and has held senior leadership roles across leading European cancer centers and oncology organizations, including EORTC, ECCO, and Cancer Core Europe. Prof. Eggermont is widely known for his contributions to melanoma and solid tumor immunotherapy, with more than 1,200 publications and major impact on the development of modern cancer immunotherapy approaches.